

## Translating New Immune Pathways into Meaningful Medicines

Biotech Showcase Sanjay S. Shukla, M.D., M.S., President & CEO January 7, 2019



#### **Forward-Looking Statements**

The following slides and any accompanying oral presentation contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as "may," "might," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "project," "intend," "future," "potential," "opportunity," or "continue," and other similar expressions are intended to identify forward-looking statements. For example, all statements we make regarding the potential therapeutic benefits of proteins derived from tRNA synthetase genes and our product candidates, including ATYR1923 and any other product candidates, the ability to successfully advance our product candidates, the timing within which we expect to initiate, receive and report data from, and complete our planned clinical trials, our ability to receive regulatory approvals for, and commercialize, our product candidates, our ability to identify and discover additional product candidates, and the ability of our intellectual property portfolio to provide protection are forwardlooking statements. All forward-looking statements are based on estimates and assumptions by our management that, although we believe to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that we expected. These risks, uncertainties and other factors are more fully described in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q, and in our other filings. The forward-looking statements in this presentation speak only as of the date of this presentation and neither we nor any other person assume responsibility for the accuracy and completeness of any forward-looking statement. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

We own various U.S. federal trademark applications and unregistered trademarks, including our company name. All other trademarks or trade names referred to in this presentation are the property of their respective owners. Solely for convenience, the trademarks and trade names in this presentation are referred to without the symbols <sup>®</sup> and <sup>™</sup>, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto.



## **Accelerating Value Creation from Novel Biology**

#### **Platform of New Biology:**

Discovery pipeline of novel therapeutic candidates based on proprietary knowledge of extracellular functions of tRNA synthetases (~300 protein compositions patented)

#### Lead Product Candidate: ATYR1923

Engineered, long acting, protein therapeutic, derived from the HARS gene, for the treatment of pulmonary sarcoidosis

#### **Financials:**


Cash, cash equivalents and investments at \$56.0m as of 9/30/2018

#### **Clinical Milestones:**

- ✓ Initiated P1b/2a Trial 4Q 2018
  - □ Interim Results 4Q 2019\*
  - □ Final Results mid-2020\*



### Extracellular tRNA Synthetase Biology Associated with Disease in Multiple Tissues




#### aTyr's current R&D focus

**Pipeline opportunities** 



### Novel tRNA Synthetase Domains Secreted Extracellularly with Non-Catalytic Functions







## **ATYR1923**

For the Treatment of Pulmonary Sarcoidosis

# Sarcoidosis: The Most Common Form of Interstitial Lung Disease








IPF: Idiopathic Pulmonary Fibrosis; CHP: Chronic Hypersensitivity Pneumonitis; CTD-ILD: Connective Tissue Disease Associated ILD

### Interstitial Lung Diseases Share Persistent Immune Engagement






Slide adapted from Dr. Steven Nathan, Medical Director, Advanced Lung Disease and Transplant Program at Inova Fairfax Hospital, Falls Church, VA

### First-in-Patient Population: Pulmonary Sarcoidosis

- Systemic inflammatory disorder characterized by the formation of granulomas (clumps of inflammatory cells) in one or more organs of the body
- CD4+ (Th1 / Th17) T-cell driven
- Usually begins in the lungs, skin or lymph nodes
- Sarcoidosis in the lungs is called pulmonary sarcoidosis and occurs in ~90% of patients

#### Unmet needs<sup>1</sup>:

- Better understanding of pathogenesis
- Prognostic stratification and targeted management
- Better therapies, with quicker onset of action and less toxicity




Baughman RP, Culver DA, Judson MA. AM J Respir Crit Care Med 2011



### **ATYR1923: Novel Engineered Protein Therapeutic**


- Active domain (iMod) is naturally occurring splice-variant of HARS that is enriched in the human lung
- Binds selectively to Neuropilin-2 (NRP2)
- Regulates a number of immune cell-types, including: T cells, Neutrophils, Macrophages, Dendritic cells





### **Receptor: Importance of NRP-2 as a Binding Partner for ATYR1923**

- Pleiotropic receptor that can bind to a number of different ligands
- Well-established role in the development of the neural and lymphatic systems
- Emerging role in the immune system; present on a number of immune cell types
- Expressed on alveolar macrophages; may play role in regulating lung inflammation <sup>(1)</sup>





 Immormino et al. Neuropilin-2 regulates airway inflammatory responses to inhaled lipopolysaccharide. Am J Physiol Lung Cell Mol Physiol 315: L202-L211. 2018.


### **Pre-Clinical Translational Estate Supports Clinical Development in ILD**

Bleomycin-Induced Lung Injury (Mouse)	<ul> <li>ATYR1923 vs. pirfenidone*</li> <li>ATYR1923 reduced fibrosis and inflammation</li> <li>Presented at ATS, May 2017</li> </ul>
Bleomycin-Induced Lung Injury (Rat)	<ul> <li>ATYR1923 vs. nintedanib**</li> <li>ATYR1923 returned lung function to normal and reduced fibrosis and inflammation</li> <li>Presented at ATS, May 2018</li> </ul>
Sclerodermatous chronic- graft vs host disease (Mouse)	<ul> <li>ATYR1923 vs. nintedanib**</li> <li>ATYR1923 reduced lung and skin fibrosis</li> <li>Presented at Scleroderma Foundation Patient Conference, July 2018</li> </ul>



### ATYR1923 Intervention in Pulmonary Sarcoidosis

#### ATYR1923 Therapeutic Hypothesis: Downregulate inflammatory insult and prevent progression to fibrosis






Hypothesized Immunopathogenesis of Sarcoidosis adapted from Iannuzzi et al, NEJM, 2007

## **Phase 1 Healthy Volunteer Study Completed**

#### Positive Phase 1 Data Announced in June 2018

- Randomized, double-blind, placebo-controlled, single ascending dose (N=36 HVs)
- ATYR1923 was generally well-tolerated with no significant adverse events
- PK profile supports the potential for a once-monthly dosing regimen





## ATYR1923 Phase 1b/2a Study in Pulmonary Sarcoidosis

Objectives	<ul> <li>Evaluate safety, tolerability, PK, and immunogenicity of multiple ascending doses of ATYR1923</li> <li>Evaluate signals of drug activity through steroid dose reduction and FDG-PET/CT changes</li> </ul>
Design	<ul> <li>Randomized, double-blind, placebo-controlled, multiple ascending dose</li> </ul>
Population	<ul> <li>Histologically confirmed pulmonary sarcoidosis</li> <li>Requiring ≥10 mg prednisone (steroid) treatment; capable of steroid taper</li> <li>Symptomatic/active disease at baseline by <sup>18F</sup>-FDG-PET/CT, Pulmonary Function Tests</li> </ul>
Dosing	<ul> <li>3 sequential cohorts, 12 patients each</li> <li>2:1 randomization</li> <li>ATYR1923 doses: 1.0, 3.0, and 5.0 mg/kg</li> </ul>
Duration	<ul><li>24-week study period</li><li>Steroid taper phase down to 5 mg by week 8</li><li>16-week maintenance phase</li></ul>
Sites	<ul> <li>Up to 12 leading pulmonary sarcoidosis centers in US</li> <li>Collaboration with the Foundation for Sarcoidosis Research</li> </ul>



## ATYR1923 Phase 1b/2a Study Endpoints

#### Primary


Safety and tolerability of multiple ascending IV ATYR1923 doses

#### Secondary

- Steroid-sparing effect
- Immunogenicity
- Pharmacokinetics (PK)
- Exploratory efficacy measures: FDG-PET/CT imaging; Lung function (FVC); Serum biomarkers; Health-related quality of life scales



### ATYR1923 Phase 1b/2a Study Schema





## ATYR1923 Phase 1b/2a Study in Pulmonary Sarcoidosis Initiated

Status	<ul> <li>US IND accepted</li> <li>Up to 12 leading Pulmonary Sarcoidosis centers in US</li> <li>Site initiation activities ongoing</li> </ul>
Timelines*	<ul> <li>Interim data: 4Q 2019</li> <li>Study completion: mid-2020</li> </ul>
Possible Future Development	<ul> <li>Registrational trial in Pulmonary Sarcoidosis</li> <li>Initiate P2 studies in other types of interstitial lung disease (e.g. CTD-ILD; CHP)</li> </ul>



## Mission: Generate Value for Patients and Shareholders

- aTyr owns IP estate directed to a potential pipeline of proteins derived from 20 tRNA synthetase genes
- ✓ ATYR1923 *in-vitro* and *in-vivo* studies support clinical development in ILD
- Identification of NRP-2 receptor for ATYR1923 elucidates greater understanding of MOA
- Positive Phase 1 data for ATYR1923
- Initiated Phase 1b/2a study of ATYR1923 in patients with pulmonary sarcoidosis
- Goal is to demonstrate safety and preliminary clinical activity in ATYR1923 pulmonary sarcoidosis trial
- Potential to expand into other ILD indications



# Thank You